The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | ViPOR: a multi-targeted therapy for the treatment of R/R DLBCL
Christopher Melani, MD, National Institutes of Health, Bethesda, MD, discusses a Phase Ib/II study (NCT03223610) investigating the use of ViPOR, a 5-drug combination regimen, for the treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). This multi-targeted therapy combines venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide. All agents were administered for a fixed duration in non-continuous cycles during the study. The ViPOR therapeutic approach was well tolerated and resulted in deep and durable remissions, with potential for cure, in 38-47% of patients, depending on the disease subtype. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
